CSL Ltd - Company Profile
Powered by 
All the data and insights you need on CSL Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date CSL Ltd Strategy Report
- Understand CSL Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
CSL Ltd (CSL) discovers, develops, manufactures, commercializes and distributes biopharmaceuticals and related products. Its portfolio encompasses plasma-derived products for the treatment of hemophilia, hereditary angioedema, von Willebrand disease, inherited primary and secondary immune deficiencies, neurological disorders, respiratory disease, and protein-based medicines for treating serious human illnesses. The company also provides products for the prevention of hemolytic disease in newborns, infection in solid organ transplant recipients and to treat specific infections for victims of trauma and burns. CSL markets an array of vaccines, anti-venoms and pharmaceutical products of various other manufacturers. The company sells its products in Australia, Germany, Switzerland, the US, the UK and other countries. CSL is headquartered in Parkville, Victoria, Australia.
Headquarters
Australia
Address
45 Poplar Road, Parkville, Melbourne, Victoria, 3052
Website
www.csl.com
Telephone
61 3 93891911
No of Employees
32,065
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CSL (ASX)
Revenue (2022)
$13.3B
26%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-2.7%
(2022 vs 2021)
Market Cap*
$88.0B
Net Profit Margin (2022)
XYZ
-22.8%
(2022 vs 2021)
* As of and is in US$
CSL Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Plasma-derived Therapies | Hizentra |
| Vaccines | Privigen |
| Diagnostics Products | Idelvion |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In February, the company signed an agreement with Genezen to award a license for Cytegrity proprietary stable production system. |
| 2024 | Regulatory Approval | In January, the company secured approval from Swissmedic for HEMGENIX to treat male adults aged above 18 years with severe or moderately severe hemophilia B. |
| 2023 | Others | In December, the company's Biologics License Application for garadacimab was accepted by the U.S. Food and Drug Administration. |
Competitor Comparison
| Key Parameters | CSL Ltd | AbbVie Inc | Bayer AG | AstraZeneca Plc | Bristol-Myers Squibb Co |
|---|---|---|---|---|---|
| Headquarters | Australia | United States of America | Germany | United Kingdom | United States of America |
| City | Melbourne | North Chicago | Leverkusen | Cambridge | Princeton |
| State/Province | Victoria | Illinois | Nordrhein-Westfalen | England | New Jersey |
| No. of Employees | 32,065 | 50,000 | 99,723 | 89,900 | 34,100 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Brian McNamee | Chairman | Executive Board | 2018 | 66 |
| Paul McKenzie | Managing Director; Chief Executive Officer | Senior Management | 2023 | 57 |
| Joy Linton | Chief Financial Officer | Senior Management | 2020 | 57 |
| Ken Lim | Executive Vice President; Chief Strategy Officer | Senior Management | - | 49 |
| Jeffrey Ball | Chief Sustainability Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward